Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

AKDOĞAN O., SÜTCÜOĞLU O., Yucel K. B., YAZICI O., ÖZET A., ÖZDEMİR N.

JOURNAL OF CANCER POLICY, cilt.44, 2025 (ESCI, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.jcpo.2025.100590
  • Dergi Adı: JOURNAL OF CANCER POLICY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, MEDLINE
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: Gastrointestinal system (GIS) cancers are a major global health challenge, with access to innovative therapies limited in resource-constrained settings. This study evaluates GIS cancer treatments in Turkey using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and examines their reimbursement status. Methods: Seventy-four treatment protocols were assessed using ESMO-MCBS, focusing on survival and quality-of-life benefits. Cost analyses of non-reimbursed protocols were conducted using the RxMedia Pharma 2024 database for a 70 kg patient. Results: Only 31 % of the protocols were reimbursed, with nearly all curative regimens covered. In contrast, most metastatic treatments were non-reimbursed, despite significant clinical benefits. Non-reimbursed protocols with ESMO-MCBS scores >= 4 had 3-month costs ranging from $1000 to $10,000. Conclusion: High-value therapies for GIS cancers remain largely inaccessible due to financial barriers. Incorporating ESMO-MCBS scores into reimbursement policies could improve access to effective treatments and align healthcare spending with clinical outcomes.